Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

6.190 -0.200 (-3.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 934,765
Open 6.360
Bid (Size) 6.000 (5,000)
Ask (Size) 6.180 (400)
Prev. Close 6.390
Today's Range 6.160 - 6.470
52wk Range 4.010 - 11.24
Shares Outstanding 77,740,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verastem (VSTM) Q4 2025 Earnings Call Transcript ↗
Verastem (VSTM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? ↗
The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2. 
Via Stocktwits
Topics Earnings

Performance

YTD
-14.4%
-14.4%
1 Month
-6.9%
-6.9%
3 Month
-38.8%
-38.8%
6 Month
-37.6%
-37.6%
1 Year
-13.1%
-13.1%

More News

Read More
Verastem Inc. (NASDAQ:VSTM) Reports Strong Q4 Revenue Beat, Narrows Loss Amid Product Launch ↗
Via Chartmill
News headline image
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects ↗
Via Stocktwits
News headline image
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗
Via Stocktwits
Topics Supply Chain
News headline image
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
From Verastem Oncology
Via Business Wire
News headline image
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Proposed Public Offering of Common Stock
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
Verastem Inc (NASDAQ:VSTM) Reports Q3 2025 Revenue Beat Amid Widened Loss ↗
Via Chartmill
News headline image
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 6.190
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 03/11/26 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 481.21M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 481M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.